Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors

@article{Williams2002PharmacokineticPharmacodynamicDI,
  title={Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors},
  author={D. Williams and J. Feely},
  journal={Clinical Pharmacokinetics},
  year={2002},
  volume={41},
  pages={343-370}
}
  • D. Williams, J. Feely
  • Published 2002
  • Medicine
  • Clinical Pharmacokinetics
  • The HMG-CoA reductase inhibitors (statins) are effective in both the primary and secondary prevention of ischaemic heart disease. As a group, these drugs are well tolerated apart from two uncommon but potentially serious adverse effects: elevation of liver enzymes and skeletal muscle abnormalities, which range from benign myalgias to life-threatening rhabdomyolysis. Adverse effects with statins are frequently associated with drug interactions because of their long-term use in older patients who… CONTINUE READING
    405 Citations
    Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
    • 105
    Drug–drug interactions that interfere with statin metabolism
    • 43
    Genetic Polymorphisms in Cytochrome P450 Enzymes
    • A. Vermes, I. Vermes
    • Medicine
    • American journal of cardiovascular drugs : drugs, devices, and other interventions
    • 2004
    • 37
    An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
    • 1
    Statins and their interactions with other lipid-modifying medications: safety issues in the elderly
    • 11
    Role of P‐glycoprotein in Statin Drug Interactions
    • 143
    Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin.
    • 13
    • Highly Influenced
    Drug interactions with statins
    • 25
    • PDF
    Cytochrome P450-mediated cardiovascular drug interactions
    • A. Scheen
    • Medicine
    • Expert opinion on drug metabolism & toxicology
    • 2011
    • 24
    • Highly Influenced